文献类型：期刊文献

英文题名：The role of the gut microbiota in the development of rheumatic diseases: a focus on fibromyalgia

作者：Zhao, Yongli[1];Xie, Xingwen[1,2]

第一作者：赵永利

通信作者：Xie, XW[1];Xie, XW[2]

机构：[1]Gansu Univ Tradit Chinese Med, Affiliated Hosp, Lanzhou, Peoples R China;[2]Gansu Univ Tradit Chinese Med, Lanzhou, Peoples R China

第一机构：甘肃中医药大学第二附属医院

通信机构：[1]corresponding author), Gansu Univ Tradit Chinese Med, Affiliated Hosp, Lanzhou, Peoples R China;[2]corresponding author), Gansu Univ Tradit Chinese Med, Lanzhou, Peoples R China.|[10735]甘肃中医药大学;[10735b845793de6ae2b30]甘肃中医药大学第二附属医院;

年份：2026

卷号：17

外文期刊名：FRONTIERS IN IMMUNOLOGY

收录：;Scopus(收录号：2-s2.0-105046133991);WOS:【SCI-EXPANDED(收录号:WOS:001822175600001)】；

基金：The author(s) declared that financial support was received for this work and/or its publication. This research was supported by the Gansu University of Chinese Medicine Graduate Innovation and Entrepreneurship Fund (No. 2025CXCY-015, No. 2025CXZX-927, No. 2025CXZX-914), the Lanzhou Talent Innovation and Entrepreneurship Project (No. 2024-RC-89), the Open Fund of the State Key Laboratory of Chinese Medicine Performance Innovation Engineering (No. SKL2025-11), and the Natural Science Foundation of Gansu Province (No. 25JRRA234).

语种：英文

外文关键词：central sensitization; dysbiosis; fibromyalgia; gut;brain axis; gut microbiota; rheumatic diseases

摘要：Fibromyalgia (FM) is a chronic widespread pain syndrome affecting 2%-4% of the population whose pathophysiology remains incompletely understood. Growing evidence implicates gut microbiota dysbiosis as a contributing factor, acting through immune, neuroendocrine, and metabolic pathways that may reinforce central sensitization. Consistent findings of reduced microbial diversity and altered metabolite profiles-including short-chain fatty acids, bile acids, and tryptophan derivatives-suggest mechanistic links between the gut and FM symptoms. Microbiota-targeted interventions such as probiotics, dietary modification, and fecal microbiota transplantation have shown preliminary benefits, though evidence remains limited by small sample sizes and methodological heterogeneity. This review synthesizes current knowledge on the role of the gut microbiota in FM within the broader context of rheumatic diseases and discusses future research directions.